Subtype
Myosarcoma
CI-CAN-00001265Explore in graph →
106 active trials1 approved drugs38 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001265Explore in graph →
Clinical trials
325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | terminated | Phase 3 | 107 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 |
| clinicaltrials |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | terminated | Phase 3 | 38 | Gynecologic Oncology GroupNETWORK | 8 | Apr 28, 2020 | clinicaltrials |
| NCT00162695 | Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood | terminated | Phase 3 | 400 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 13, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jun 24, 2026source: clinicaltrials